<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820452</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI302A201</org_study_id>
    <nct_id>NCT04820452</nct_id>
  </id_info>
  <brief_title>A Study of IBI302 in Patients With nAMD</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active-controlled Phase II Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed for multi-center, randomized, double-blind, active-controlled phase II&#xD;
      study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related&#xD;
      macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The visual efficacy of IBI302</measure>
    <time_frame>Baseline to week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>other visual effects of IBI302</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>the proportion if BCVA improvement ≥0,5,10 or 15 letters at week 12, 28, 36 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the anatomical effects of IBI302 on OCT</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>the mean change of central subfield thickness from BL to week 52 at week 12, 28, 36 and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the anatomical effects of IBI302 on FFA</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>the change of CNV area, CNV leakage area, total lesion area from BL to week 36 or 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety of IBI302</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>the incidence of ocular AE or any systemic AE, TEAE, SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IBI302</measure>
    <time_frame>Baseline to week 52</time_frame>
    <description>the positive rate of anti-drug antibody and neutralizing antibody</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>cohort 1 IBI302 treated with high dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 1 IBI302 treated with low dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose IBI302</intervention_name>
    <description>Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection</description>
    <arm_group_label>cohort 1 IBI302 treated with low dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose IBI302</intervention_name>
    <description>High dose IBI302 intravitreal injection given as every other month after three loading monthly injection</description>
    <arm_group_label>cohort 1 IBI302 treated with high dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intraocular injection</description>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient ≥ 50 yrs. of age.&#xD;
&#xD;
          2. Active subfoveal or parafoveal CNV secondary to neovascular AMD.&#xD;
&#xD;
          3. BCVA score of 24-73 letters using ETDRS charts in the study eye.&#xD;
&#xD;
          4. Willing and able to sign informed consent form and comply with visit and study&#xD;
             procedures per protocol.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Concomitant diseases that may cause subjects fail to respond to the treatment or&#xD;
             confuse the interpretation of the study results;&#xD;
&#xD;
          2. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥25mmHg despite the&#xD;
             standardized treatment);&#xD;
&#xD;
          3. Presence of active intraocular or periocular inflammation or infection;&#xD;
&#xD;
          4. Prior any treatment of following in the study eye:&#xD;
&#xD;
               1. Anti-VEGF therapy or anti-complement therapy within 3 months prior to screening;&#xD;
&#xD;
               2. Laser photocoagulation within 3 months prior to screening;&#xD;
&#xD;
               3. Photodynamic therapy or vitreoretinal surgery;&#xD;
&#xD;
               4. Intraocular glucocorticoid injection within 6 months prior to enrollment;&#xD;
&#xD;
          5. Presence of any systemic disease: including but not limited toactive infections (such&#xD;
             as active viral hepatitis); unstable angina; cerebrovascular accident or transient&#xD;
             cerebral ischemia (within 6 months prior to selection); myocardial infarction (within&#xD;
             6 months prior to selection); serious arrhythmia requiring medical treatment; liver,&#xD;
             kidney or metabolic diseases; or malignant tumor;&#xD;
&#xD;
          6. History of severe hypersensitivity/allergy to active ingredients or any excipients of&#xD;
             the study drug, or fluorescein and povidone iodine;&#xD;
&#xD;
          7. Pregnant or lactating women or women preparing to become pregnant or breastfeeding&#xD;
             during the study period;&#xD;
&#xD;
          8. Participated in any clinical study of any other drug within three months prior to&#xD;
             enrollment, or attempted to participate in other drug trials during the study;&#xD;
&#xD;
          9. Other conditions unsuitable for enrollment judged by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yating Liu</last_name>
    <phone>86 15821084695</phone>
    <email>yating.liu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

